[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-001", "question": "A 58-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide develops progressive disease with new liver metastases. He is switched to docetaxel plus prednisone. After 6 cycles, his PSA declines by 80% and liver lesions shrink, but he develops new-onset bilateral gynecomastia, mild hyperpigmentation of palmar creases, and worsening fatigue. Serum studies show: testosterone 12 ng/dL (low), LH 0.1 mIU/mL (low), FSH 0.2 mIU/mL (low), cortisol 4 mcg/dL (8 AM, low), ACTH 15 pg/mL (inappropriately normal), TSH 0.8 mIU/L, free T4 1.0 ng/dL. What is the most likely underlying mechanism for his new symptoms?", "options": ["Secondary adrenal insufficiency due to docetaxel-induced autoimmune hypophysitis", "Ectopic ACTH secretion from prostate cancer cells transforming to small cell neuroendocrine carcinoma", "Inhibition of CYP17A1 by residual enzalutamide leading to combined glucocorticoid and mineralocorticoid deficiency", "Docetaxel-induced primary testicular failure with subsequent feedback suppression of gonadotropins", "Paraneoplastic production of beta-hCG by treatment-emergent neuroendocrine-differentiated prostate cancer"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture suggests combined glucocorticoid and androgen deficiency with low ACTH, consistent with secondary adrenal insufficiency due to central suppression. Enzalutamide is a potent androgen receptor inhibitor but also inhibits multiple CYP enzymes, including CYP17A1, which is required for glucocorticoid and androgen synthesis. When docetaxel suppresses tumor burden, residual enzalutamide (with a long half-life) continues to block adrenal steroidogenesis, causing a late-presenting adrenal crisis. Ectopic ACTH would elevate ACTH; autoimmune hypophysitis typically elevates TSH and causes other pituitary deficiencies; primary testicular failure elevates LH/FSH; beta-hCG causes gynecomastia but not adrenal insufficiency.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: New gynecomastia, palmar crease hyperpigmentation, fatigue after docetaxel + prednisone response; labs show low cortisol with inappropriately normal ACTH (suggesting secondary adrenal insufficiency), low testosterone/LH/FSH (secondary hypogonadism), normal TSH/T4. These imply central suppression, but hyperpigmentation typically indicates primary adrenal insufficiency with elevated ACTH, not normal ACTH as here. Main logical issue(s): Contradiction—stem includes hyperpigmentation (classic for high ACTH in primary AI) but labs show inappropriately normal ACTH with low cortisol, making the vignette incoherent and unsolvable; underspecified regarding prednisone's role in HPA suppression, requiring assumptions about duration/dose effects. Main medical accuracy issue(s): Keyed answer C inaccurately attributes CYP17A1 inhibition to enzalutamide (actually abiraterone's mechanism); rationale misstates enzalutamide's pharmacology, contradicting standard knowledge that enzalutamide is an AR antagonist without direct CYP17 effects; hyperpigmentation-lab mismatch is clinically implausible without explanation. Minimal fix: Edit stem to remove 'mild hyperpigmentation of palmar creases' and change keyed answer to a new option like 'HPA axis suppression from chronic prednisone use,' making it unambiguous and accurate.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: New gynecomastia, palmar crease hyperpigmentation, fatigue after docetaxel + prednisone response; labs show low cortisol with inappropriately normal ACTH (suggesting secondary adrenal insufficiency), low testosterone/LH/FSH (secondary hypogonadism), normal TSH/T4. These imply central suppression, but hyperpigmentation typically indicates primary adrenal insufficiency with elevated ACTH, not normal ACTH as here. Main logical issue(s): Contradiction—stem includes hyperpigmentation (classic for high ACTH in primary AI) but labs show inappropriately normal ACTH with low cortisol, making the vignette incoherent and unsolvable; underspecified regarding prednisone's role in HPA suppression, requiring assumptions about duration/dose effects. Main medical accuracy issue(s): Keyed answer C inaccurately attributes CYP17A1 inhibition to enzalutamide (actually abiraterone's mechanism); rationale misstates enzalutamide's pharmacology, contradicting standard knowledge that enzalutamide is an AR antagonist without direct CYP17 effects; hyperpigmentation-lab mismatch is clinically implausible without explanation. Minimal fix: Edit stem to remove 'mild hyperpigmentation of palmar creases' and change keyed answer to a new option like 'HPA axis suppression from chronic prednisone use,' making it unambiguous and accurate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Recurrent acute headache, photophobia, neck stiffness within 48 hours post-IVIG in CVID patient; LP with elevated opening pressure (28 cm H2O) but normal WBC (2/μL), protein (40 mg/dL), glucose (60 mg/dL, ratio ~0.63); negative Gram stain/culture; normal contrast MRI; history of two similar milder episodes post-IVIG. These point to IVIG-induced aseptic meningitis, with question focusing on prevention while maintaining immune protection.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating details (timing, LP findings excluding infection, recurrence pattern) to identify aseptic meningitis and evaluate interventions for risk reduction without compromising CVID management.\\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that IVIG can cause aseptic meningitis via IgG peaks/cytokine release; SCIG switch is evidence-based to minimize peaks while sustaining IgG levels, per immunology guidelines (e.g., AAAAI). Alternatives correctly portrayed as less optimal (e.g., steroids not routine, formulation change/slower infusion reduce but don't eliminate risk in susceptible patients).\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Recurrent acute headache, photophobia, neck stiffness within 48 hours post-IVIG in CVID patient; LP with elevated opening pressure (28 cm H2O) but normal WBC (2/μL), protein (40 mg/dL), glucose (60 mg/dL, ratio ~0.63); negative Gram stain/culture; normal contrast MRI; history of two similar milder episodes post-IVIG. These point to IVIG-induced aseptic meningitis, with question focusing on prevention while maintaining immune protection.\nMain logical issue(s), if any: None; stem provides sufficient discriminating details (timing, LP findings excluding infection, recurrence pattern) to identify aseptic meningitis and evaluate interventions for risk reduction without compromising CVID management.\nMain medical accuracy issue(s), if any: None; aligns with established knowledge that IVIG can cause aseptic meningitis via IgG peaks/cytokine release; SCIG switch is evidence-based to minimize peaks while sustaining IgG levels, per immunology guidelines (e.g., AAAAI). Alternatives correctly portrayed as less optimal (e.g., steroids not routine, formulation change/slower infusion reduce but don't eliminate risk in susceptible patients).\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-003", "question": "An 87‑year‑old man with moderate Alzheimer dementia (MoCA 14/30), hypertension, and chronic kidney disease (eGFR 28 mL/min/1.73m²) is admitted from assisted living for acute confusion and agitation. He has been on donepezil 10 mg daily for 3 years. In the ED, he receives lorazepam 1 mg IM for severe agitation, with minimal effect. Inpatient medications include amlodipine, losartan, and aspirin. Over 48 hours, he develops persistent non‑rhythmic myoclonic jerks of the face and limbs, fluctuating alertness, and autonomic instability (HR 110-140, BP 170/95). EEG shows generalized periodic discharges with triphasic morphology. MRI brain is unchanged from baseline (moderate atrophy). What is the most likely diagnosis?", "options": ["Creutzfeldt‑Jakob disease", "Serotonin syndrome from an undetected SSRI", "Donepezil toxicity in the setting of acute kidney injury", "Nonconvulsive status epilepticus due to underlying neurodegeneration", "Acute anticholinergic delirium from a newly started medication"], "answer": "C", "answer_index": 2, "explanation": "The presentation with myoclonus, autonomic instability, altered mental status, and triphasic waves on EEG in a patient on donepezil with advanced CKD suggests donepezil toxicity. Donepezil is renally excreted, and acute kidney injury (even mild) can precipitate toxicity. Triphasic waves are classically associated with metabolic/toxic encephalopathies, including acetylcholinesterase inhibitor toxicity. Creutzfeldt‑Jakob disease would show rapid progression and MRI diffusion abnormalities. Serotonin syndrome requires a serotonergic agent. Nonconvulsive status typically shows rhythmic epileptiform discharges. Anticholinergic delirium causes dry skin, not myoclonus or triphasic waves.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: Elderly patient with moderate Alzheimer dementia on long-term donepezil, stable CKD (eGFR 28), acute admission for confusion/agitation, lorazepam minimal effect, development of non-rhythmic myoclonus, fluctuating alertness, autonomic instability (tachycardia, hypertension), EEG with triphasic waves suggestive of toxic/metabolic encephalopathy, unchanged MRI. Clues point toward toxic encephalopathy, but no trigger for acute donepezil toxicity after 3 years (e.g., no AKI, dehydration, or labs indicated).\\nMain logical issue(s), if any: Underspecified - the stem lacks evidence of acute kidney injury or any precipitant for sudden donepezil accumulation in chronic stable CKD, requiring an unstated assumption to select C as uniquely best; without it, toxicity timing is unexplained, potentially allowing D (nonconvulsive status) as alternative given periodic discharges in dementia, though triphasic morphology favors metabolic cause.\\nMain medical accuracy issue(s), if any: Mostly aligns with standards, but autonomic features (tachycardia, hypertension) atypical for cholinergic toxicity (usually bradycardia/hypotension); donepezil is primarily hepatically metabolized with minor renal excretion, so toxicity in stable CKD without precipitant is unrealistic; triphasic waves correctly associated with toxic encephalopathy.\\nMinimal fix: Add to stem: 'Admission labs show eGFR 18 mL/min/1.73m² (baseline 28), indicating acute kidney injury.'\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: Elderly patient with moderate Alzheimer dementia on long-term donepezil, stable CKD (eGFR 28), acute admission for confusion/agitation, lorazepam minimal effect, development of non-rhythmic myoclonus, fluctuating alertness, autonomic instability (tachycardia, hypertension), EEG with triphasic waves suggestive of toxic/metabolic encephalopathy, unchanged MRI. Clues point toward toxic encephalopathy, but no trigger for acute donepezil toxicity after 3 years (e.g., no AKI, dehydration, or labs indicated).\nMain logical issue(s), if any: Underspecified - the stem lacks evidence of acute kidney injury or any precipitant for sudden donepezil accumulation in chronic stable CKD, requiring an unstated assumption to select C as uniquely best; without it, toxicity timing is unexplained, potentially allowing D (nonconvulsive status) as alternative given periodic discharges in dementia, though triphasic morphology favors metabolic cause.\nMain medical accuracy issue(s), if any: Mostly aligns with standards, but autonomic features (tachycardia, hypertension) atypical for cholinergic toxicity (usually bradycardia/hypotension); donepezil is primarily hepatically metabolized with minor renal excretion, so toxicity in stable CKD without precipitant is unrealistic; triphasic waves correctly associated with toxic encephalopathy.\nMinimal fix: Add to stem: 'Admission labs show eGFR 18 mL/min/1.73m² (baseline 28), indicating acute kidney injury.'", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Metastatic HER2-positive breast cancer progressing on maintenance trastuzumab/pertuzumab after first-line therapy; new pancreatic lesion with HER2 IHC 3+ but no amplification by NGS, PIK3CA H1047R mutation, ER-/PR- status, no prior CDK4/6i or everolimus. These indicate progression on dual HER2 blockade, potential HER2-low/discordant status, and PIK3CA activation in hormone receptor-negative disease, favoring a switch to antibody-drug conjugate effective in resistant/HER2-low settings. Main logical issue(s): None; stem provides sufficient details for discriminating T-DXd as superior to continuing prior therapy (A), older regimens (C), or HR-targeted options (D, E) inappropriate for ER-/PR- tumor. Main medical accuracy issue(s): None; aligns with NCCN guidelines preferring T-DXd as second-line for HER2-positive MBC post-trastuzumab/pertuzumab/taxane progression, with activity in HER2-low and PIK3CA-mutated cases regardless of HR status; D/E are for HR-positive disease only. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Metastatic HER2-positive breast cancer progressing on maintenance trastuzumab/pertuzumab after first-line therapy; new pancreatic lesion with HER2 IHC 3+ but no amplification by NGS, PIK3CA H1047R mutation, ER-/PR- status, no prior CDK4/6i or everolimus. These indicate progression on dual HER2 blockade, potential HER2-low/discordant status, and PIK3CA activation in hormone receptor-negative disease, favoring a switch to antibody-drug conjugate effective in resistant/HER2-low settings. Main logical issue(s): None; stem provides sufficient details for discriminating T-DXd as superior to continuing prior therapy (A), older regimens (C), or HR-targeted options (D, E) inappropriate for ER-/PR- tumor. Main medical accuracy issue(s): None; aligns with NCCN guidelines preferring T-DXd as second-line for HER2-positive MBC post-trastuzumab/pertuzumab/taxane progression, with activity in HER2-low and PIK3CA-mutated cases regardless of HR status; D/E are for HR-positive disease only. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-005", "question": "A 28‑year‑old woman with idiopathic anaphylaxis presents with recurrent episodes of urticaria, angioedema, wheezing, and hypotension occurring 2-3 times monthly despite high‑dose antihistamines and montelukast. She undergoes exhaustive evaluation: normal tryptase, negative specific IgE to foods/venoms/drugs, no mastocytosis on bone marrow biopsy, and no physical urticaria triggers. During a supervised oral challenge to placebo in clinic, she develops identical symptoms with hypotension. Serum collected during the event shows elevated prostaglandin D2 (PGD2) but normal histamine and tryptase. Which therapy is most likely to be effective in preventing future episodes?", "options": ["Omalizumab (anti‑IgE)", "Rituximab (anti‑CD20)", "Imatinib (tyrosine kinase inhibitor)", "Continuous intravenous epinephrine infusion", "NSAID (e.g., indomethacin) prior to suspected triggers"], "answer": "E", "answer_index": 4, "explanation": "Elevated PGD2 with normal histamine/tryptase during symptoms suggests a prostaglandin‑mediated disorder, possibly a mast cell activation syndrome variant or idiopathic flush‑related anaphylaxis. NSAIDs inhibit cyclooxygenase and reduce PGD2 production, which can prevent episodes in select patients with prostaglandin‑driven symptoms. Omalizumab targets IgE‑mediated pathways, not primarily prostaglandin‑mediated. Rituximab is for autoimmune conditions. Imatinib is for mastocytosis with KIT mutations. Continuous epinephrine is not a preventive therapy and carries high risk.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Recurrent idiopathic anaphylaxis symptoms (urticaria, angioedema, wheezing, hypotension) despite antihistamines/montelukast; exhaustive negative evaluation (normal tryptase, negative IgE, no mastocytosis, no triggers); symptoms during placebo challenge with elevated PGD2 but normal histamine/tryptase, pointing to prostaglandin-mediated mechanism. Main logical issue(s), if any: None; the stem provides sufficient discriminating details (isolated PGD2 elevation) to identify a unique best therapy without contradictions or underspecification, ruling out IgE/mast cell/KIT pathways. Alternatives are appropriately inferior: A (omalizumab) targets IgE, irrelevant here; B (rituximab) for autoimmunity, unsupported; C (imatinib) for mutated mastocytosis, biopsy-negative; D (epinephrine infusion) not preventive and risky. Main medical accuracy issue(s), if any: None; aligns with current allergy/immunology consensus on prostaglandin-driven anaphylaxis variants, where NSAIDs can prophylactically inhibit COX-mediated PGD2 synthesis, consistent with guidelines (e.g., AAAAI on mast cell activation syndromes). Item is clinically realistic and board-relevant. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Recurrent idiopathic anaphylaxis symptoms (urticaria, angioedema, wheezing, hypotension) despite antihistamines/montelukast; exhaustive negative evaluation (normal tryptase, negative IgE, no mastocytosis, no triggers); symptoms during placebo challenge with elevated PGD2 but normal histamine/tryptase, pointing to prostaglandin-mediated mechanism. Main logical issue(s), if any: None; the stem provides sufficient discriminating details (isolated PGD2 elevation) to identify a unique best therapy without contradictions or underspecification, ruling out IgE/mast cell/KIT pathways. Alternatives are appropriately inferior: A (omalizumab) targets IgE, irrelevant here; B (rituximab) for autoimmunity, unsupported; C (imatinib) for mutated mastocytosis, biopsy-negative; D (epinephrine infusion) not preventive and risky. Main medical accuracy issue(s), if any: None; aligns with current allergy/immunology consensus on prostaglandin-driven anaphylaxis variants, where NSAIDs can prophylactically inhibit COX-mediated PGD2 synthesis, consistent with guidelines (e.g., AAAAI on mast cell activation syndromes). Item is clinically realistic and board-relevant. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's severe symptomatic aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm², syncope, declining energy), high surgical risk, and TAVR candidacy, with the question seeking the factor most strongly arguing against TAVR. These clues emphasize shared decision-making focused on procedural benefits versus risks, aligning with guidelines requiring >12 months life expectancy for TAVR to justify risks. Option C (life expectancy <12 months due to metastatic lung cancer) directly contraindicates based on futility. No main logical issues; the stem is coherent, options discriminable, and C is uniquely best without contradictions or underspecification. No main medical accuracy issues; the item aligns with ACC/AHA guidelines on TAVR indications, emphasizing life expectancy >1 year, and correctly notes that frailty, moderate-severe MR (which may improve post-TAVR), recent bleeding (relative, timeable), and small AAA (<5 cm threshold for repair) are not absolute contraindications. Minimal fix: None needed, as the item is already unambiguous and accurate; if enhancing, add 'per current guidelines' to the stem for explicitness.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's severe symptomatic aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm², syncope, declining energy), high surgical risk, and TAVR candidacy, with the question seeking the factor most strongly arguing against TAVR. These clues emphasize shared decision-making focused on procedural benefits versus risks, aligning with guidelines requiring >12 months life expectancy for TAVR to justify risks. Option C (life expectancy <12 months due to metastatic lung cancer) directly contraindicates based on futility. No main logical issues; the stem is coherent, options discriminable, and C is uniquely best without contradictions or underspecification. No main medical accuracy issues; the item aligns with ACC/AHA guidelines on TAVR indications, emphasizing life expectancy >1 year, and correctly notes that frailty, moderate-severe MR (which may improve post-TAVR), recent bleeding (relative, timeable), and small AAA (<5 cm threshold for repair) are not absolute contraindications. Minimal fix: None needed, as the item is already unambiguous and accurate; if enhancing, add 'per current guidelines' to the stem for explicitness.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]